$CELG (Celgene Corporation)

$CELG {{ '2016-03-01T13:36:47+0000' | timeago}} • SEC

$CELG's sales from breast cancer treating drug Abraxane for 2015 increased by 14.1% from last year. This was primarily due to increased unit volumes in both the U.S. and international markets reflecting increased acceptance of the product for the treatments of both metastatic adenocarcinoma of the pancreas and non-small cell lung cancer (NSCLC).

$CELG {{ '2017-11-16T14:30:32+0000' | timeago}} • Announcement

$CELG and its partner $BLUE reported that FDA granted Breakthrough Therapy Designation, which will expedite the review of the plasma cell cancer treating therapy. This was based on the preliminary data from the ongoing phase 1 study of the therapy. In March 2013, Celgene and Bluebird Bio entered into a strategic alliance in the field of oncology.

$CELG {{ '2017-10-31T16:07:34+0000' | timeago}} • Announcement

In a confidential license agreement, $CELG and $LCI enter into a settlement related to Celgene's Thalomid drug, which is used to treat the plasma cell cancer. This agreement allows Lannett to manufacture and market a generic thalidomide product in the US from Aug. 1, 2019, or earlier under certain circumstances.

$CELG {{ '2017-10-30T23:17:02+0000' | timeago}} • Announcement

$CELG cut down its FY17 GAAP EPS outlook from $5.36-5.62 range to $4.78-5.19 range. For FY20, the drugmaker slashed its total net product sales target from the previous target of greater than $21Bil to $19-20Bil range and adjusted EPS target was reduced from the previous target of greater than $13 to greater than $12.50.

$CELG {{ '2017-10-30T22:55:16+0000' | timeago}} • Announcement

Despite higher profit and revenues in 3Q17, $CELG cut down its outlook for 2017 and 2020. Profit spiked nearly six times to $988MM or $1.21 per share, while revenue rose 10% to $3.29Bil. Product sales were up 11% to $3.28Bil, helped by the increase in sales of Revlimid, Pomalyst/Imnovid, Otezla and Abraxane drugs.

$CELG {{ '2017-10-26T12:55:41+0000' | timeago}} • Infographic

$CELG Celgene Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following the recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

$CELG {{ '2017-09-07T15:10:29+0000' | timeago}} • Announcement

$CELG gets a pause from FDA as it partially holds the drugmaker's five clinical trials and one clinical trial fully. All of these trials involve cancer drug Durvalumab. Celgene added that patients enrolled in the partial hold trials may remain on the treatment and those who are on full clinical hold trial will be discontinued from the treatment.

$CELG {{ '2017-08-01T17:51:34+0000' | timeago}} • Announcement

$CELG and $AGIO said Idhifa (enasidenib) was granted approval from FDA for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 mutation. The approval was based on results from the Phase I/II study. AML is a cancer of blood and bone marrow marked by rapid disease progression.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

$CELG {{ '2017-07-06T14:11:20+0000' | timeago}} • Announcement

Upon closing of $CELG/$BGNE transaction, which is expected during 3Q17, BeiGene to receive upfront license fees of $263MM and $150MM in equity investment. BeiGene will also be eligible to receive up to $980MM in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317, a drug used to treat cancers.

$CELG {{ '2017-07-06T14:08:05+0000' | timeago}} • Announcement

$CELG enters into a collaborative agreement with biopharma company $BGNE to treat tumor cancers. Celgene will acquire 32.7MM or 5.9% of BeiGene's ordinary shares at $4.58 per share. BeiGene to acquire Celgene's commercial operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China.

$CELG {{ '2017-06-19T12:38:44+0000' | timeago}} • Announcement

Pharma firm $CELG said it would present data from various clinical studies evaluating its  investigational agents for the treatment of blood cancer, at the European Hematology Association’s annual meeting to be held in Madrid, Spain, from June 22 to 25. The data will support the role of Celgene’s therapies as the foundation of myeloma research.

$CELG {{ '2017-06-19T10:48:16+0000' | timeago}} • Announcement

$CELG announced results from interim analysis of Magnify, a phase 3b, randomized, open-label, multicenter study of Revlimid (lenalidomide) plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Lymphoma a group of blood cell tumors that develop from lymphocytes (a type of white blood cell).

$CELG {{ '2017-06-14T11:57:50+0000' | timeago}} • Announcement

Celgene International Sarl, a subsidiary of $CELG, announced results from the phase 2a SLE-001 trial evaluating CC-220, its investigational, oral immunomodulatory compound. A trend toward greater improvement with CC-220 treatment compared with placebo in multiple measures of disease activity was observed in patients with lupus.

Recent Transcripts

BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
ARQL (ArQule Inc.)
Thursday, November 9 2017 - 2:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
ATHX (Athersys, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
AGIO (Agios Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like